Influence of DAOA gene variants on antipsychotic response after switch to aripiprazole

Psychiatry Research

Volumn 178, Issue 2, 2010, Pages 430-432

  Pae, Chi Un ^a,b   Chiesa, Alberto ^c   Serretti, Alessandro ^c  

^a The Catholic University of Korea   (South Korea)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Aripiprazole; Pharmacogenetics; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; DEXTRO AMINO ACID OXIDASE;

ALLELE; ARTICLE; FEMALE; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIPSYCHOTIC AGENTS; BRIEF PSYCHIATRIC RATING SCALE; CARRIER PROTEINS; FEMALE; HUMANS; KOREA; MALE; NEUROPSYCHOLOGICAL TESTS; PHARMACOGENETICS; PIPERAZINES; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; SCHIZOPHRENIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 77953807245     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2010.04.017     Document Type: Article

References (25)

1. Abou Jamra R., Schmael C., Cichon S., Rietschel M., Schumacher J., Nothen M.M. The G72/G30 gene locus in psychiatric disorders: a challenge to diagnostic boundaries?. Schizophrenia Bulletin 2006, 32:599-608.
2. Andreasen N.C. The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. British Journal of Psychiatry 1989, 49-58. Suppl.
3. Barnes T.R. A rating scale for drug-induced akathisia. British Journal of Psychiatry 1989, 154:672-676.
4. Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
5. Branch P.R. Abnormal involuntary movement scale (AIMS). Early Clinical Drug Evaluation Unit Intercom 1975, 4:3-6.
6. Chumakov I., Blumenfeld M., Guerassimenko O., Cavarec L., Palicio M., Abderrahim H., Bougueleret L., Barry C., Tanaka H., La Rosa P., Puech A., Tahri N., Cohen-Akenine A., Delabrosse S., Lissarrague S., Picard F.P., Maurice K., Essioux L., Millasseau P., Grel P., Debailleul V., Simon A.M., Caterina D., Dufaure I., Malekzadeh K., Belova M., Luan J.J., Bouillot M., Sambucy J.L., Primas G., Saumier M., Boubkiri N., Martin-Saumier S., Nasroune M., Peixoto H., Delaye A., Pinchot V., Bastucci M., Guillou S., Chevillon M., Sainz-Fuertes R., Meguenni S., Aurich-Costa J., Cherif D., Gimalac A., Van Duijn C., Gauvreau D., Ouellette G., Fortier I., Raelson J., Sherbatich T., Riazanskaia N., Rogaev E., Raeymaekers P., Aerssens J., Konings F., Luyten W., Macciardi F., Sham P.C., Straub R.E., Weinberger D.R., Cohen N., Cohen D. Genetic and physiological data implicating the new human gene G72 and the gene for d-amino acid oxidase in schizophrenia. Proceeding of the National Academy of Science U S A 2002, 99:13675-13680.
7. Cohen J. Statistical power analysis for the behavioral sciences 1988, 8-14. Lawrence Erlbaum Associates, Hillsdale, New Jersey.
8. Detera-Wadleigh S.D., McMahon F.J. G72/G30 in schizophrenia and bipolar disorder: review and meta-analysis. Biological Psychiatry 2006, 60:106-114.
9. Flemenbaum A., Zimmermann R.L. Inter- and intra-rater reliability of the brief psychiatric rating scale. Psychological Reports 1973, 32:783-792.
10. Guy W. Clinical Global Impression. Assesment manual for psychopharmacology 1976, 217-222. Department of Health Education and Welfare, Washington DC: U.S.
11. Hall J., Whalley H.C., Moorhead T.W., Baig B.J., McIntosh A.M., Job D.E., Owens D.G., Lawrie S.M., Johnstone E.C. Genetic variation in the DAOA (G72) gene modulates hippocampal function in subjects at high risk of schizophrenia. Biological Psychiatry 2008, 64:428-433.
12. Kotaka T., Ujike H., Okahisa Y., Takaki M., Nakata K., Kodama M., Inada T., Yamada M., Uchimura N., Iwata N., Sora I., Iyo M., Ozaki N., Kuroda S. G72 gene is associated with susceptibility to methamphetamine psychosis. Progress in Neuropsychopharmacology and Biological Psychiatry 2009, 33:1046-1049.
13. Kvajo M., Dhilla A., Swor D.E., Karayiorgou M., Gogos J.A. Evidence implicating the candidate schizophrenia/bipolar disorder susceptibility gene G72 in mitochondrial function. Molecular Psychiatry 2008, 13:685-696.
14. Martineau M., Baux G., Mothet J.P. d-serine signalling in the brain: friend and foe. Trends in Neuroscience 2006, 29:481-491.
15. Owen M.J., Craddock N., Jablensky A. The genetic deconstruction of psychosis. Schizophrenia Bulletin 2007, 33:905-911.
16. Pae C.U., Serretti A., Chiesa A., Mandelli L., Lee C., Kim J., De Ronchi D., Paik I.H. Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study. European Neuropsychopharmacology 2009, 19:562-570.
17. Pae C.U., Chiesa A., Mandelli L., De Ronchi D., Serretti A. No influence of FAT polymorphisms in response to aripiprazole. Journal of Human Genetics 2010, 55:32-36.
18. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry 1998, 59(Suppl 20):22-33.
19. Shi J., Badner J.A., Gershon E.S., Liu C. Allelic association of G72/G30 with schizophrenia and bipolar disorder: a comprehensive meta-analysis. Schizophrenia Research 2008, 98:89-97.
20. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatric Scandinavica Supplementum 1970, 212:11-19.
21. Sodhi M., Wood K.H., Meador-Woodruff J. Role of glutamate in schizophrenia: integrating excitatory avenues of research. Expert Reviews of Neurotherapeutics 2008, 8:1389-1406.
22. StatSoft, I., 1995, STATISTICA per Windows, StatSoft Italia srl.
23. Sullivan P.F. Spurious genetic associations. Biological Psychiatry 2007, 61:1121-1126.
24. Williams N.M., Green E.K., Macgregor S., Dwyer S., Norton N., Williams H., Raybould R., Grozeva D., Hamshere M., Zammit S., Jones L., Cardno A., Kirov G., Jones I., O'Donovan M.C., Owen M.J., Craddock N. Variation at the DAOA/G30 locus influences susceptibility to major mood episodes but not psychosis in schizophrenia and bipolar disorder. Archives of General Psychiatry 2006, 63:366-373.
25. Yue W., Kang G., Zhang Y., Qu M., Tang F., Han Y., Ruan Y., Lu T., Zhang J., Zhang D. Association of DAOA polymorphisms with schizophrenia and clinical symptoms or therapeutic effects. Neuroscience Letters 2007, 416:96-100.